Image 1_Sepsis in Internal Medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers.tiff by Gaetano Zizzo (15853004)

“…Median length of stay (LOS) was 14 days, and mean ward-to-intensive care unit (ICU) transfer and in-hospital mortality rates were 11 and 26%, respectively; significant differences were observed over the years, with LOS peaks preceding mortality peaks by 1 year. …”

Image 2_Sepsis in Internal Medicine: blood culture-based subtypes, hospital outcomes, and predictive biomarkers.tiff by Gaetano Zizzo (15853004)

“…Median length of stay (LOS) was 14 days, and mean ward-to-intensive care unit (ICU) transfer and in-hospital mortality rates were 11 and 26%, respectively; significant differences were observed over the years, with LOS peaks preceding mortality peaks by 1 year. …”

Developmental change in 5-HT_1A binding in known cause of death controls (predischarge and postdischarge combined). by Hannah C. Kinney (10280975)

The impact of nano-curcumin on cell viability and proliferation in breast cancer cells. by Taraneh Givi (22793530)

“…(C, D) MTT assays were conducted on MCF7-S and MCF7-TR cells following nano-curcumin treatment. Cell viability significantly decreased at all tested time points. (E, F) mRNA Expression levels <i>PI3K</i>, <i>AKT1</i>, <i>mTOR</i>, <i>NF-KB</i>, <i>Cyclin D1</i>, <i>DILA1</i> and <i>PTEN</i> in breast cancer cells. …”

Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors by Xiaorui Han (1401655)

“…Its cell survival rate was significantly higher than <b>GS-4997</b>, indicating its good safety in normal human liver LO2 cells. …”

Supplementary file 1_Cyperotundone promotes chemosensitivity of breast cancer via SRSF1.tif by Chao Li (145513)

“…SRSF1 regulated alternative splicing of MYO1B to enhance the ability of drug resistance. Knockdown of SRSF1 significantly decreased expression of full-length MYO1B protein in drug-resistant BC cells (P < 0.05). …”

Table 1_Cyperotundone promotes chemosensitivity of breast cancer via SRSF1.docx by Chao Li (145513)

“…SRSF1 regulated alternative splicing of MYO1B to enhance the ability of drug resistance. Knockdown of SRSF1 significantly decreased expression of full-length MYO1B protein in drug-resistant BC cells (P < 0.05). …”

Supplementary file 2_Cyperotundone promotes chemosensitivity of breast cancer via SRSF1.tif by Chao Li (145513)

“…SRSF1 regulated alternative splicing of MYO1B to enhance the ability of drug resistance. Knockdown of SRSF1 significantly decreased expression of full-length MYO1B protein in drug-resistant BC cells (P < 0.05). …”

Supplementary file 3_Cyperotundone promotes chemosensitivity of breast cancer via SRSF1.tif by Chao Li (145513)

“…SRSF1 regulated alternative splicing of MYO1B to enhance the ability of drug resistance. Knockdown of SRSF1 significantly decreased expression of full-length MYO1B protein in drug-resistant BC cells (P < 0.05). …”

Ictogenic changes in input correlation and adaptation gains are associated with increased dynamical variability during baseline activity. by Scott Rich (9873638)

“…<b>B</b>: <i>U</i>_<i>e</i> and <i>U</i>_<i>i</i> Normalized SD during baseline activity (top) and SLE rate (bottom) in the default model compared to two non-ictogenic scenarios— decreased from 50.0 to 40.0 and decreased from 1.2 to .8. …”

Transmission electron microscopy (TEM) photographs. by Jingjing Chen (293564)

“…<b>B-D</b>: At 3 days to 2 weeks after injury, collagenous fibers and myofibroblasts significantly increased in the stroma, and the EBM remained absent (Magnification=7000). …”

Image 3_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Table 2_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.docx by Marisa R. Young (7919255)

Image 2_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 11_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 7_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 8_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 6_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 4_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)

Image 9_No change in key HIV target cell markers following initiation of three progestin-based hormonal contraception methods: findings from the CHIME study.tiff by Marisa R. Young (7919255)